Patients with adverse mood effects from combined oral contraceptives have lower levels of prepulse inhibition than healthy controls

Psychoneuroendocrinology

Volumn 33, Issue 4, 2008, Pages 487-496

  Borgström, Anna ^a   Kask, Kristiina ^a   Gulinello, Maria ^b   Odlind, Viveca ^a,c   Sundström Poromaa, Inger ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

Adverse mood; Combined oral contraceptives; Estradiol; Menstrual cycle; Prepulse inhibition; Progesterone; Startle response

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ACOUSTIC REFLEX; ACOUSTIC STARTLE REFLEX; ADULT; ARTICLE; CONTROLLED STUDY; ELECTROMYOGRAPHY; FEMALE; HUMAN; MENTAL INSTABILITY; ORAL CONTRACEPTION; ORBICULARIS OCULI MUSCLE; PREPULSE INHIBITION; PRIORITY JOURNAL; SIDE EFFECT; STARTLE REFLEX; STIMULUS RESPONSE; WHITE NOISE;

ACOUSTIC STIMULATION; ADULT; AFFECTIVE SYMPTOMS; BLINKING; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; HUMANS; INHIBITION (PSYCHOLOGY); NEURAL INHIBITION; REFERENCE VALUES; SENSORY THRESHOLDS; STARTLE REACTION; STATISTICS, NONPARAMETRIC;

EID: 41849095929     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2008.01.007     Document Type: Article

References (39)

1. Andreen L., Sundstrom-Poromaa I., Bixo M., Andersson A., Nyberg S., and Backstrom T. Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology 30 (2005) 212-224
2. Bast T., Zhang W.N., and Feldon J. Hyperactivity, decreased startle reactivity, and disrupted prepulse inhibition following disinhibition of the rat ventral hippocampus by the gaba(a) receptor antagonist picrotoxin. Psychopharmacology (Berl) 156 (2001) 225-233
3. Bjorn I., Sundstrom-Poromaa I., Bixo M., Nyberg S., Backstrom G., and Backstrom T. Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J. Clin. Endocrinol. Metab. 88 (2003) 2026-2030
4. Cullberg J. Mood changes and menstrual symptoms with different gestagen/estrogen combinations. A double blind comparison with a placebo. Acta Psychiatr. Scand. Suppl. 236 (1972) 1-86
5. Davis M. Neurochemical modulation of sensory-motor reactivity: acoustic and tactile startle reflexes. Neurosci. Biobehav. Rev. 4 (1980) 241-263
6. Davis M., Rainnie D., and Cassell M. Neurotransmission in the rat amygdala related to fear and anxiety. Trends Neurosci. 17 (1994) 208-214
7. Epperson C.N., Haga K., Mason G.F., Sellers E., Gueorguieva R., Zhang W., Weiss E., Rothman D.L., and Krystal J.H. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch. Gen. Psychiatry 59 (2002) 851-858
8. Epperson C.N., Pittman B., Czarkowski K.A., Stiklus S., Krystal J.H., and Grillon C. Luteal-phase accentuation of acoustic startle response in women with premenstrual dysphoric disorder. Neuropsychopharmacology 32 (2007) 2190-2198
9. Ernst U., Baumgartner L., Bauer U., and Janssen G. Improvement of quality of life in women using a low-dose desogestrel-containing contraceptive: results of an observational clinical evaluation. Eur. J. Contracept. Reprod. Health Care 7 (2002) 238-243
10. Freeman E.W. Evaluation of a unique oral contraceptive (yasmin) in the management of premenstrual dysphoric disorder. Eur. J. Contracept. Reprod. Health Care 7 Suppl. 3 (2002) 27-34
11. A receptor in the amygdala after progesterone withdrawal. Eur. J. Neurosci. 17 (2003) 641-648
12. Halbreich U., Backstrom T., Eriksson E., O'Brien S., Calil H., Ceskova E., Dennerstein L., Douki S., Freeman E., Genazzani A., Heuser I., Kadri N., Rapkin A., Steiner M., Wittchen H.U., and Yonkers K. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol. Endocrinol. 23 (2007) 123-130
13. Hammarback S., and Backstrom T. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with gnrh-agonist versus placebo. Acta Obstet. Gynecol. Scand. 67 (1988) 159-166
14. Hammarback S., Ekholm U.B., and Backstrom T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol. (Copenh) 125 (1991) 132-137
15. Heldt S.A., Green A., and Ressler K.J. Prepulse inhibition deficits in gad65 knockout mice and the effect of antipsychotic treatment. Neuropsychopharmacology 29 (2004) 1610-1619
16. Japha K., and Koch M. Picrotoxin in the medial prefrontal cortex impairs sensorimotor gating in rats: reversal by haloperidol. Psychopharmacology (Berl) 144 (1999) 347-354
17. Joffe H., Cohen L.S., and Harlow B.L. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am. J. Obstet. Gynecol. 189 (2003) 1523-1530
18. Jovanovic T., Szilagyi S., Chakravorty S., Fiallos A.M., Lewison B.J., Parwani A., Schwartz M.P., Gonzenbach S., Rotrosen J.P., and Duncan E.J. Menstrual cycle phase effects on prepulse inhibition of acoustic startle. Psychophysiology 41 (2004) 401-406
19. Kask K., Gulinello M., Backstrom T., Geyer M.A., and Sundstrom-Poromaa I. Patients with premenstrual dysphoric disorder have increased startle response across both cycle phases and lower levels of prepulse inhibition during the late luteal phase of the menstrual cycle. Neuropsychopharmacology (2007) 10.1038/sj.npp.1301599
20. Larsson G., Blohm F., Sundell G., Andersch B., and Milsom I. A longitudinal study of birth control and pregnancy outcome among women in a Swedish population. Contraception 56 (1997) 9-16
21. Lee Y., and Davis M. Role of the hippocampus, the bed nucleus of the stria terminalis, and the amygdala in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. J. Neurosci. 17 (1997) 6434-6446
22. Lewin B., Fugl-Meyer K., and Helmius G. Sex i Sverige (1996), Folkhälsoinstitutet
23. Odlind V., Milsom I., Persson I., and Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?. Acta Obstet. Gynecol. Scand. 81 (2002) 482-490
24. Oinonen K.A., and Mazmanian D. To what extent do oral contraceptives influence mood and affect?. J. Affect. Disord. 70 (2002) 229-240
25. Pearlstein T.B., Bachmann G.A., Zacur H.A., and Yonkers K.A. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 72 (2005) 414-421
26. Robinson S.A., Dowell M., Pedulla D., and McCauley L. Do the emotional side-effects of hormonal contraceptives come from pharmacologic or psychological mechanisms?. Med. Hypotheses 63 (2004) 268-273
27. Sanders S.A., Graham C.A., Bass J.L., and Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 64 (2001) 51-58
28. Sangthawan M., and Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 μg on premenstrual symptoms. Contraception 71 (2005) 1-7
29. Schmidt P.J., Nieman L.K., Danaceau M.A., Adams L.F., and Rubinow D.R. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N. Engl. J. Med. 338 (1998) 209-216
30. Sundstrom I., Ashbrook D., and Backstrom T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 22 (1997) 25-38
31. Sundstrom I., Nyberg S., and Backstrom T. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 17 (1997) 370-381
32. Sundstrom I., Andersson A., Nyberg S., Ashbrook D., Purdy R.H., and Backstrom T. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 67 (1998) 126-138
33. Sundstrom I., Backstrom T., Wang M., Olsson T., Seippel L., and Bixo M. Premenstrual syndrome, neuroactive steroids and the brain. Gynecol. Endocrinol. 13 (1999) 206-220
34. Sundstrom I., Nyberg S., Bixo M., Hammarback S., and Backstrom T. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet. Gynecol. Scand. 78 (1999) 891-899
35. Swerdlow N.R., Auerbach P., Monroe S.M., Hartston H., Geyer M.A., and Braff D.L. Men are more inhibited than women by weak prepulses. Biol. Psychiatry 34 (1993) 253-260
36. Swerdlow N.R., Hartman P.L., and Auerbach P.P. Changes in sensorimotor inhibition across the menstrual cycle: implications for neuropsychiatric disorders. Biol. Psychiatry 41 (1997) 452-460
37. Toufexis D.J., Davis C., Hammond A., and Davis M. Progesterone attenuates corticotropin-releasing factor-enhanced but not fear-potentiated startle via the activity of its neuroactive metabolite, allopregnanolone. J. Neurosci. 24 (2004) 10280-10287
38. Van den Buuse M., and Eikelis N. Estrogen increases prepulse inhibition of acoustic startle in rats. Eur. J. Pharmacol. 425 (2001) 33-41
39. Wang M., Seippel L., Purdy R.H., and Backstrom T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one. J. Clin. Endocrinol. Metab. 81 (1996) 1076-1082